RxDoctor Payments DataLook up a doctor →

Kenneth Liss, DO

Nephrology · Eatontown, NJNPI 1033125315

Payments from drug & device makers

$270,833in general payments, 2019–2025

Across 712 payments — averaging $380.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$165K
  • CSL Behring$59K
  • Otsuka America Pharmaceutical, Inc.$16K
  • Amgen$12K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$8K
  • Janssen Research & Development, LLC$5K
  • plus $6K from 36 others

What the payments were for

  • Consulting fees$1,5502%
  • Speaking & faculty fees$57,44676%
  • Travel & lodging$4,1175%
  • Food & beverage$11,78616%
  • Education$2520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$270,833 in reported general payments places this provider in the 95th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$331,970
Medicare patients
683
Services billed
17,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol115$143,672
Tolvaptan43$79,393
JardianceEmpagliflozin50$76,196
EliquisApixaban38$41,262
LokelmaSodium Zirconium Cyclosilicate29$35,352
KerendiaFinerenone27$30,204
MounjaroTirzepatide21$25,510
VelphoroSucroferric Oxyhydroxide16$19,657
Sevelamer Carbonate46$11,665
EdarbiAzilsartan Medoxomil19$8,108
VascepaIcosapent Ethyl13$6,524
Febuxostat18$3,350
Midodrine Hcl19$3,240
Doxazosin Mesylate134$2,918
Amlodipine Besylate294$2,803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$165,141$179,024144 claims
Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan$8,098$79,39343 claims
Boehringer IngelheimJardiance$192$76,19650 claims
BayerKerendia$466$30,20427 claims
Fresenius USA Marketing, Inc.Velphoro$492$19,65716 claims
Arbor Pharmaceuticals, Inc.Edarbi$599$8,10819 claims
ANI Pharmaceuticals, Inc.Valsartan$48$2,49060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Eatontown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →